Transcatheter arterial chemoembolization using cisplatin powder mixed with degradable starch microspheres for colorectal liver metastases after FOLFOX failure: Results of a phase I/II study

Journal of Vascular and Interventional Radiology

Volumn 24, Issue 1, 2013, Pages 56-65

  Nishiofuku, Hideyuki ^a   Tanaka, Toshihiro ^a   Matsuoka, Masaki ^b   Otsuji, Toshio ^b   Anai, Hiroshi ^a   Sueyoshi, Satoru ^a   Inaba, Yoshitaka ^c   Koyama, Fumikazu ^a   Sho, Masayuki ^a   Nakajima, Yoshiyuki ^a   Kichikawa, Kimihiko ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

^b Dongo Hospital   (Japan)

^c AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

5 fluorouracil; 5 FU; 5 FU, leucovorin plus irinotecan; 5 FU, leucovorin plus oxaliplatin; alanine aminotransferase; ALT; aspartate aminotransferase; AST; carcinoembryonic antigen; CEA; CI; confidence interval; degradable starch microspheres; DLT; dose limiting toxicity; DSM; FOLFIRI; FOLFOX; H PFS; hepatic progression free survival; OS; overall survival; PFS; progression free survival; RECIST; Response Evaluation Criteria In Solid Tumors

Indexed keywords

BEVACIZUMAB; CETUXIMAB; CISPLATIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; STARCH MICROSPHERE;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHEMOEMBOLIZATION; CHOLECYSTITIS; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE ESCALATION; DRUG FEVER; DRUG FORMULATION; DRUG TREATMENT FAILURE; FATIGUE; FEMALE; HEPATIC ARTERY; HUMAN; HYPERBILIRUBINEMIA; HYPERKALEMIA; HYPERTRANSAMINASEMIA; HYPOALBUMINEMIA; HYPONATREMIA; LEUKOPENIA; LIVER ABSCESS; LIVER DYSFUNCTION; LIVER METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PAIN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

ABSORBABLE IMPLANTS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CATHETERIZATION, PERIPHERAL; CHEMOEMBOLIZATION, THERAPEUTIC; CISPLATIN; COLORECTAL NEOPLASMS; DRUG COMBINATIONS; EMBOLIZATION, THERAPEUTIC; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; MALE; MICROSPHERES; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; POWDERS; STARCH; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84871899583     PISSN: 10510443     EISSN: 15357732     Source Type: Journal    
DOI: 10.1016/j.jvir.2012.09.010     Document Type: Article

References (34)

1. R.M. Goldberg, D.J. Sargent, and R.F. Morton A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer J Clin Oncol 22 2004 23 30
2. C. Tournigand, T. André, and E. Achille FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study J Clin Oncol 22 2004 229 237
3. H. Hurwitz, L. Fehrenbacher, and W. Novotny Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342
4. D.J. Jonker, C.J. O'Callaghan, and C.S. Karapetis Cetuximab for the treatment of colorectal cancer N Engl J Med 357 2007 2040 2048
5. E. Van Cutsem, C.H. Köhne, and E. Hitre Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer N Engl J Med 360 2009 1408 1417
6. J. Souglakos, N. Androulakis, and K. Syrigos FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG) Br J Cancer 94 2006 798 805
7. H.X. Chen, M. Mooney, and M. Boron Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301 J Clin Oncol 24 2006 3354 3360
8. Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics, 2010. CA Cancer J Clin 2010; 60:277-230.
9. H. Nishiofuku, T. Tanaka, and T. Aramaki Hepatic arterial infusion of 5-fluorouracil for patients with liver metastases from colorectal cancer refractory to standard systemic chemotherapy: a multicenter, retrospective analysis Clin Colorectal Cancer 9 2010 305 310
10. M. Ducreux, M. Ychou, and A. Laplanche Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer J Clin Oncol 23 2005 4881 4887
11. V. Boige, D. Malka, and D. Elias Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure Ann Surg Oncol 15 2008 219 226
12. R.C. Martin, J. Joshi, and K. Robbins Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study Ann Surg Oncol 18 2011 192 198
13. R.C. Martin, K. Robbins, and D. Tomalty Transarterial chemoembolisation (TACE) using irinotecan-loaded beads for the treatment of unresectable metastases to the liver in patients with colorectal cancer: an interim report World J Surg Oncol 7 2009 80
14. N. Kemeny, K. Israel, and D. Niedzwiecki Randomized study of continuous infusion fluorouracil versus fluorouracil plus cisplatin in patients with metastatic colorectal cancer J Clin Oncol 8 1990 313 318
15. W. Scheithauer, D. Depisch, and G. Kornek Randomized comparison of fluorouracil and leucovorin therapy versus fluorouracil, leucovorin, and cisplatin therapy in patients with advanced colorectal cancer Cancer 73 1994 1562 1568
16. R. Mancini, M. Tedesco, and C. Garufi Hepatic arterial infusion (HAI) of cisplatin and systemic fluorouracil in the treatment of unresectable colorectal liver metastases Anticancer Res 23 2003 1837 1841
17. B. Qin, K. Kato, and K. Mitsugi Feasibility study of ambulatory continuous infusion of 5-fluorouracil followed by cisplatin through hepatic artery for metastatic colorectal cancer Cancer Chemother Pharmacol 57 2006 114 119
18. O. Rixe, W. Ortuzar, and M. Alvarez Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel Biochem Pharmacol 52 1996 1855 1865
19. N. Kitada, K. Takara, and T. Minegaki Factors affecting sensitivity to antitumor platinum derivatives of human colorectal tumor cell lines Cancer Chemother Pharmacol 62 2008 577 584
20. D. Civalleri, M. Esposito, and R.A. Fulco Liver and tumor uptake and plasma pharmacokinetic of arterial cisplatin administered with and without starch microspheres in patients with liver metastases Cancer 68 1991 988 994
21. B. Lindell, K.F. Aronsen, B. Nosslin, and U. Rothman Studies in pharmacokinetics and tolerance of substances temporarily retained in the liver by microsphere embolization Ann Surg 187 1978 95 99
22. M. Yoshikawa, N. Ono, and H. Yodono Phase II study of hepatic arterial infusion of a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma Hepatol Res 38 2008 474 483
23. M. Kondo, M. Morimoto, and K. Numata Hepatic arterial infusion therapy with a fine powder formulation of cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombosis Jpn J Clin Oncol 41 2011 69 75
24. M. Moriguchi, T. Takayama, and M. Nakamura Phase I/II study of a fine-powder formulation of cisplatin for transcatheter arterial chemoembolization in hepatocellular carcinoma Hepatol Res 40 2010 369 375
25. N. Maeda, K. Osuga, and H. Higashihara In vitro characterization of cisplatin-loaded superabsorbent polymer microspheres designed for chemoembolization J Vasc Interv Radiol 21 2010 877 881
26. N.A. Mayr, T. Taoka, and W.T. Yuh Method and timing of tumor volume measurement for outcome prediction in cervical cancer using magnetic resonance imaging Int J Radiat Oncol Biol Phys 52 2002 14 22
27. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
28. B. Drewinko, B.W. Brown, and J.A. Gottlieb The effect of cis-diamminedichloroplatinum (II) on cultured human lymphoma cells and its therapeutic implications Cancer Res 33 1973 3091 3095
29. D.J. Gallagher, M. Capanu, G. Raggio, and N. Kemeny Hepatic arterial infusion plus systemic irinotecan in patients with unresectable hepatic metastases from colorectal cancer previously treated with systemic oxaliplatin: a retrospective analysis Ann Oncol 18 2007 1995 1999
30. M. Peeters, T.J. Price, and A. Cervantes Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer J Clin Oncol 28 2010 4706 4713
31. Y. Arai, Y. Inaba, and Y. Takeuchi Intermittent hepatic arterial infusion of high-dose 5FU on a weekly schedule for liver metastases from colorectal cancer Cancer Chemother Pharmacol 40 1997 526 530
32. Y. Chen, Z. Yan, and J. Wang Hepatic arterial infusion with oxaliplatin, irinotecan and doxifluridine for unresectable liver metastases of colorectal cancer Anticancer Res 30 2010 3045 3049
33. M.F. Mulcahy, R.J. Lewandowski, and S.M. Ibrahim Radioembolization of colorectal hepatic metastases using yttrium-90 microspheres Cancer 115 2009 1849 1858
34. K. Wasser, F. Giebel, and R. Fischbach Transarterial chemoembolization of liver metastases of colorectal carcinoma using degradable starch microspheres (Spherex): personal investigations and review of the literature Radiologe 45 2005 633 643